Dr Renu Ragupathi speaks to ecancer about the real-world safety and efficacy data of CDK4/6 inhibitors plus endocrine therapy in female patients aged over 65 years with advanced hormone receptor-positive HER-2 negative breast cancer.

This study investigates 53 patients aged 65 with metastatic breast cancer, focusing on treatment with palbociclib and abemaciclib.

It assesses progression-free survival, toxicity, and tolerability.

While most tolerate the treatment, some require dose adjustments due to common toxicities like neutropenia.

The findings reveal similar progression-free survival rates across age groups and emphasize the need for better representation of elderly patients in clinical trials.